Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer

Phase 2

Completed

Conditions: Recurrent Prostate Cancer

Interventions: Drug: leuprolide acetate
Drug: pazopanib hydrochloride
Drug: goserelin acetate

First Posted Date: 2007-03-30

Last Posted Date: 2016-02-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 37

Registration Number: NCT00454571

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States

Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Phase 1

Completed

Conditions: Extensive Stage Lung Small Cell Carcinoma
Recurrent Lung Small Cell Carcinoma

Interventions: Drug: Carboplatin
Drug: Cisplatin
Drug: Etoposide
Other: Laboratory Biomarker Analysis
Other: Placebo Administration
Drug: Sunitinib Malate

First Posted Date: 2007-03-28

Last Posted Date: 2023-04-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 156

Registration Number: NCT00453154

Locations: 🇺🇸
Arroyo Grande Community, Arroyo Grande, California, United States
🇺🇸
PCR Oncology, Arroyo Grande, California, United States
🇺🇸
East Bay Radiation Oncology Center, Castro Valley, California, United States

and more 122 locations

A Randomized Multicenter Double-Blind CT to Evaluate the Efficacy and Safety of Mycophenolate Mofetil . . .

Phase 3

Terminated

Conditions: Interstitial Cystitis
Painful Bladder Syndrome

Interventions: Drug: Mycophenolate Mofetil
Drug: Placebo
Drug: Mycofenolate Mofetil (MMF)

First Posted Date: 2007-03-26

Last Posted Date: 2010-01-14

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 210

Registration Number: NCT00451867

Locations: 🇺🇸
Univeristy of California San Diego, San Diego, California, United States
🇺🇸
Stanford University Medical center, Stanford, California, United States
🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States

and more 8 locations

Botulinum Toxin Injection for the Management of BPH

Phase 2

Completed

Conditions: Benign Prostatic Hyperplasia

Interventions: Drug: botulinum toxin type A (BoNT/A)

First Posted Date: 2007-03-23

Last Posted Date: 2020-04-21

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 134

Registration Number: NCT00451191

Locations: 🇺🇸
University of Colorado Health Sciences Center, Denver, Colorado, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

and more 4 locations

Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer

Phase 1

Completed

Conditions: Stage I Prostate Cancer
Stage II Prostate Cancer
Adenocarcinoma of the Prostate
Prostate Cancer

Interventions: Drug: diindolylmethane
Drug: placebo
Procedure: therapeutic conventional surgery
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2007-03-22

Last Posted Date: 2015-12-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 45

Registration Number: NCT00450229

Locations: 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States

Pazopanib in Treating Patients With Newly Diagnosed or Locally and/or Regionally Recurrent Breast Cancer That Can Be Removed By Surgery

Phase 1

Terminated

Conditions: Stage IIA Breast Cancer
Male Breast Carcinoma
Recurrent Breast Carcinoma
Stage IIB Breast Cancer
Stage IA Breast Cancer
Stage IB Breast Cancer
Stage IIIA Breast Cancer

Interventions: Drug: Pazopanib Hydrochloride
Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Other: Pharmacological Study
Other: Laboratory Biomarker Analysis

First Posted Date: 2007-03-22

Last Posted Date: 2015-03-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 19

Registration Number: NCT00450879

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies

Recruiting

Conditions: Colon Cancer
Prostate Cancer
Liver Cancer
Lung Cancer
Breast Cancer

First Posted Date: 2007-03-22

Last Posted Date: 2025-06-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 750

Registration Number: NCT00451022

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Flutamide (Eulexin)
Drug: Sargramostim (GM-CSF, Leukine)
Biological: PROSTVAC-F/ TRICOM
Biological: PROSTVAC-V/TRICOM

First Posted Date: 2007-03-22

Last Posted Date: 2018-11-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 64

Registration Number: NCT00450463

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
🇺🇸
Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Phase 2

Completed

Conditions: Chronic Myelomonocytic Leukemia
de Novo Myelodysplastic Syndromes
Myelodysplastic Syndromes
Secondary Myelodysplastic Syndromes

Interventions: Drug: sunitinib malate

First Posted Date: 2007-03-22

Last Posted Date: 2018-09-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 10

Registration Number: NCT00451048

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇨🇦
London Regional Cancer Program, London, Ontario, Canada
🇨🇦
Odette Cancer Centre- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

and more 1 locations

Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer

Phase 2

Completed

Conditions: Adenocarcinoma of the Prostate
Stage I Prostate Cancer
Stage II Prostate Cancer
Stage III Prostate Cancer

Interventions: Other: placebo
Procedure: therapeutic conventional surgery
Other: laboratory biomarker analysis
Drug: lycopene

First Posted Date: 2007-03-22

Last Posted Date: 2019-12-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 10

Registration Number: NCT00450749

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy